Literature DB >> 15766657

Matrix metalloproteinases target protease-activated receptors on the tumor cell surface.

Duanqing Pei1.   

Abstract

Matrix metalloproteinases, or MMPs, have been implicated in tumor invasion and metastasis by virtue of their ability to degrade the extracellular matrix (ECM) barrier. However, MMPs are also capable of cleaving non-ECM molecules. The protease-activated receptors (PARs) are the latest MMP targets. The thrombin receptor PAR1 has now been shown to be cleaved and activated on the tumor cell surface by stromal-derived MMP1. The resulting PAR1 activates intracellular G proteins to turn on the migratory and invasive program in tumor cells. This MMP-PAR axis may represent a novel signaling pathway communicating between tumor and stromal cells during tumor progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15766657     DOI: 10.1016/j.ccr.2005.02.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  24 in total

1.  GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis.

Authors:  Lei Xu; Shahinoor Begum; Jeremy D Hearn; Richard O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

2.  Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.

Authors:  Anika Agarwal; Lidija Covic; Leila M Sevigny; Nicole C Kaneider; Katherine Lazarides; Gissou Azabdaftari; Sheida Sharifi; Athan Kuliopulos
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

3.  Matrix Metalloproteinase 1 Causes Vasoconstriction and Enhances Vessel Reactivity to Angiotensin II via Protease-Activated Receptor 1.

Authors:  William H Nugent; Nikita Mishra; Jerome F Strauss; Scott W Walsh
Journal:  Reprod Sci       Date:  2015-10-04       Impact factor: 3.060

Review 4.  Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.

Authors:  Juan R Cubillos-Ruiz; Melanie Rutkowski; Jose R Conejo-Garcia
Journal:  Cell Cycle       Date:  2010-01-26       Impact factor: 4.534

5.  Membranous type matrix metalloproteinase 16 induces human prostate cancer metastasis.

Authors:  Chunwa Jiang; Juanjing Wang; Chen Dong; Wei Wei; Jiang Li; Xiaomeng Li
Journal:  Oncol Lett       Date:  2017-07-07       Impact factor: 2.967

6.  Mutations in bone marrow-derived stromal stem cells unmask latent malignancy.

Authors:  JeanMarie Houghton; Hanchen Li; Xueli Fan; Yingwang Liu; Jian Hua Liu; Varada P Rao; Theofilos Poutahidis; Christie L Taylor; Erin A Jackson; Christine Hewes; Stephen Lyle; Anna Cerny; Glennice Bowen; Jan Cerny; Nathan Moore; Evelyn A Kurt-Jones; Susan E Erdman
Journal:  Stem Cells Dev       Date:  2010-08       Impact factor: 3.272

7.  Migratory activity of human breast cancer cells is modulated by differential expression of xanthine oxidoreductase.

Authors:  Mehdi A Fini; David Orchard-Webb; Beata Kosmider; Jeremy D Amon; Robert Kelland; Gayle Shibao; Richard M Wright
Journal:  J Cell Biochem       Date:  2008-11-01       Impact factor: 4.429

8.  Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents.

Authors:  Victoria Smith; Gregory J Wirth; Heinz-Herbert Fiebig; Angelika M Burger
Journal:  Cancer Genomics Proteomics       Date:  2008 Sep-Oct       Impact factor: 4.069

Review 9.  Matrix metalloproteinases and protein tyrosine kinases: potential novel targets in acute lung injury and ARDS.

Authors:  Yael Aschner; Rachel L Zemans; Cory M Yamashita; Gregory P Downey
Journal:  Chest       Date:  2014-10       Impact factor: 9.410

10.  Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma.

Authors:  Ivy A W Ho; Kelly Y W Chan; Wai-Hoe Ng; Chang M Guo; Kam M Hui; Philip Cheang; Paula Y P Lam
Journal:  Stem Cells       Date:  2009-06       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.